We have an active research program covering a wide range of topics related to oral and parenteral drug delivery. Listed below are selected references and patents describing work that has been done in our laboratories and those of our collaborators:
Kish PE, Tsume Y, Kijek P, Lanigan TM, Hilfinger JM, Roessler BJ. Bile Acid - Oligopeptide Conjugates Interact with DNA and Facilitate Transfection. Mole Pharm (2007) Jan-Feb;4(1):95-103.
Parks E, Hilfinger JM, Zimmermann EM, Roessler BJ. Gene transfer via oral composite nano/microparticles to murine intestinal tissue. Gastroenterology, 118:A3044, (2000).
Chamberlain JR, Shaw MH, Hilfinger JM, Zimmermann EM, Roessler BJ. Recombinant adenovirus serotype switching for analysis of efficiency and route of intestinal cell entry. Gastroenterology, 118:A671, (2000).
Matthews C, Jenkins G, Hilfinger JM, and Davidson B. Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther. (1999) Sep; 6(9): 1558-64.
Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharmaceutical Development Technology, 3(3):373-83, (1998).
Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson BL. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Therapy, 5(6):740-6, (1998)
E. Walter, M.A. Croyle, B.L.Davidson, B.J. Roessler, J.M. Hilfinger and G.L. Amidon, Adenovirus mediated gene transfer to intestinal epithelial cells as a potential approach for oral delivery of peptides and proteins, J.Cont. Rel. 46, 75 (1997).
Walter E, Croyle MA, Davidson B, Roessler BJ, Hilfinger JM, Amidon GL. Caco-2 cells as an in vitro model for adenoviral gene transfer to the gut epithelium. (1997), J. Controlled Release 46:57-68.
